BSP Spring Meeting 2023
Schedule : Back to Jan Pieter Koopman

Rapid induction of clinical tolerance in a placebo-controlled clinical trial investigating repeated controlled exposure to Schistosoma mansoni

Wed12 Apr02:30pm(15 mins)
Where:
Appleton Tower 2
Jan Pieter  Koopman

Authors

JP Koopman1; JJ Janse1; EL Houlder1; OA Lamers1; GV Roozen1; A Van Diepen1; JC Sijtsma1; ST Hilt1; MY van der Stoep1; IM van Amerongen-Westra1; EA Brienen1; LJ Wammes1; L van Lieshout1; GJ van Dam1; PL Corstjens1; M Yazdanbakhsh1; CH Hokke1; M Roestenberg11 Leiden University Medical Centre, Netherlands

Discussion

Epidemiological data from endemic settings suggests that (partial) immunity to schistosomiasis develops over time, and is likely enhanced by repeated infections and treatments leading to enhanced or prolonged antigen exposure. Moreover, animal studies have demonstrated that protection can be achieved after repeated immunisation with irradiated cercariae. In this study, we aimed to investigate the protective efficacy and safety of consecutive exposure-treatment cycles with Schistosoma mansoni (Sm) in healthy, schistosome-naïve participants using the single-sex controlled human Sm infection model. We enrolled 24 participants who were randomised (1:1) to either three (reinfection) or one (infection control) exposures to 20 male cercariae. The infection control group received two mock exposures first. Treatment with praziquantel (or placebo for infection controls) was given 8 weeks after the first and second (mock) exposure. All participants were treated with praziquantel 12 weeks after the third exposure. Throughout the study, adverse events were collected as well as serum to measure circulating anodic antigen (CAA) secreted by juvenile and adult worms to determine infection status. All but one participant completed follow-up. The percentage of participants with detectable infection after the final exposure (CAA ≥ 1.0 pg/mL) in the reinfection group was 82% (9/11) and 92% (11/12) in the infection control group. In the reinfection group, more related adverse events were reported after the first infection (45%) as compared to the second (27%) and third infection (28%). Severe acute schistosomiasis (AS) was observed in both groups after the first infection (2 out of 12 in reinfection group and 2 out of 12 in infection control group), but no AS was reported after the subsequent infections. In conclusion, repeated Sm infection led to clinical tolerance, but did not result in (sterile) protection. Further investigation into the underlying immune response will result in better understanding of immunity to schistosomes.

supporting document

Hosted By

British Society for Parasitology (BSP)

We are science based Charitable Incorporated Organisation

Get the App

Get this event information on your mobile by
going to the Apple or Google Store and search for 'myEventflo'
iPhone App
Android App
www.myeventflo.com/2485